Page 37 - 2021_10-Haematologica-web

Novel immunotherapies in MM
49. Raje NS, Siegel DS, Jagannath S, et al. Idecabtagene vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma: analyses of high-risk subgroups in the KarMMa study. Blood. 2020;136(Suppl 1):37-38.
50.Zhao J, Lin Q, Song Y, Liu D. Universal CAR, universal T cells, and universal CAR T cells. J Hematol Oncol. 2018;11(1):132.
51. Xu J, Chen LJ, Yang SS, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci U S A. 2019;116(19):9543-9551.
52. Wang BY, Zhao WH, Liu J, et al. Long-term follow-up of a phase 1, first-in-human open- label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell matu- ration antigen (BCMA), in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Blood. 2019;134(Suppl 1):579.
53. Madduri D, Usmani SZ, Jagannath S, et al. Results from CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM). Blood. 2019;134(Suppl 1):577.
54.Berdeja J, Madduri D, Usmani SZ, et al. Update of CARTITUDE-1: a phase Ib/II study of JNJ-4528, a B-cell maturation anti- gen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma. J Clin Oncol. 2020;38(15-Suppl):8505.
55. Madduri D, Berdeja JG, Usmani SZ, et al. CARTITUDE-1: phase 1b/2 study of cilta- cabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma. Blood. 2020;136(Suppl 1):22-25.
56. Mailankody S, Matous JV, Liedtke M, et al. Universal: an allogeneic first-in-human study of the anti-BCMA ALLO-715 and the
anti-CD52 ALLO-647 in relapsed/refractory multiple myeloma. Blood. 2020;136(Suppl 1):24-25.
57.Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19- positive lymphoid tumors. N Engl J Med. 2020;382(6):545-553.
58. D'Agostino M, Raje N. Anti-BCMA CAR T- cell therapy in multiple myeloma: can we do better? Leukemia. 2020;34(1):21-34.
59. Leone P, Solimando AG, Malerba E, et al. Actors on the scene: immune cells in the myeloma niche. Front Oncol. 2020;10: 599098.
60. Wudhikarn K, Mailankody S, Smith EL. Future of CAR T cells in multiple myeloma. Hematology Am Soc Hematol Educ Program. 2020;2020(1):272-279.
61. Shah UA, Mailankody S. CAR T and CAR NK cells in multiple myeloma: expanding the targets. Best Pract Res Clin Haematol. 2020;33(1):101141.
haematologica | 2021; 106(10)
2565